The Mayo Clinic's E-Health Venture
This article was originally published in Start Up
It's not just IPO-lusting entrepreneurs and VCs jumping onto the E-Health bandwagon: two major medical institutions, Johns Hopkins University and the Mayo Clinic also want a piece of the action. In 1996, JHU and Aetna US Healthcare formed a joint venture to launch a consumer information website. More recently, the Mayo Clinic announced that it would follow suit by setting up its own Internet firm, with backing from the Shansby group, a San Francisco-based private equity company. Revenues generated by the Mayo site, which will include interactive services, are earmarked for Clinic research and educational activities.
You may also be interested in...
Formed by Kalamazoo-based Pharmacia alumni, AureoGen Biosciences Inc. is genetically engineering cyclic peptides to create second-generation, resistance-proof anti-infective and anti-fungal therapeutics.
Pain seems as close to a sure bet as the pharmaceutical industry has to offer. Forecasts call for the worldwide analgesic market, already $38 billion in 2002, to grow at a 20% annual clip, nearly doubling to $75 billion by the year 2010. For new drug developers, pain also has the advantage of offering clearly definable endpoints-less pain-and a relatively short duration for clinical trials. No surprise then that more than 200 companies have a hand in developing or marketing pain therapeutics. Among them, the three young companies profiled here-AlgoRx Pharmaceuticals Inc., Algos Therapeutics Inc., and TheraQuest Biosciences LLC.
Ambrx is using its technology for engineering proteins with novel amino acids--beyond the 20 that oocur in nature--to enhance the properties of proteins whose potential therapeutic uses, as well as liabilities, are known.